MEK Is a Therapeutic and Chemopreventative Target in Squamous Cell Carcinoma.
Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Charles H
CH
Adelmann
Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Kimberly A
KA
Truong
Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Roger J
RJ
Liang
Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Varun
V
Bansal
Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Leah
L
Gandee
Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Rachael C
RC
Saporito
Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Woojin
W
Lee
Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Lili
L
Du
Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Courtney
C
Nicholas
Department of Molecular & Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Marco
M
Napoli
Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Barbara
B
Mino
Department of Dermatology, Jefferson University, Philadelphia, Pennsylvania, USA.
Andrew P
AP
South
Centre Molecular Medicine, University of Dundee, Ninewells Hospital and Medical School, Dundee, Scotland.
Charlotte M
CM
Proby
Jacqui Wood Cancer Centre, University of Dundee, Ninewells Hospital and Medical School, Dundee, Scotland.
Irene M
IM
Leigh
Department of Molecular Biology, Baylor College of Medicine, Houston, Texas, USA.
Cristian
C
Coarfa
Department of Molecular & Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Elsa R
ER
Flores
Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Dermatology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Electronic address: kytsai@mdanderson.org.
Kenneth Y
KY
Tsai
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D001384:Azetidines / Q000494:pharmacology / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D045744:Cell Line, Tumor; D016922:Cellular Senescence / Q000187:drug effects; D006801:Humans; D020928:Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors*; D058990:Molecular Targeted Therapy / Q000379:methods; D010880:Piperidines / Q000494:pharmacology / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D011728:Pyridones / Q000494:pharmacology / Q000627:therapeutic use; D011744:Pyrimidinones / Q000494:pharmacology / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000188:drug therapy*; D023041:Xenograft Model Antitumor Assays
D000970:Antineoplastic Agents; D001384:Azetidines; D010880:Piperidines; D047428:Protein Kinase Inhibitors; D011728:Pyridones; D011744:Pyrimidinones; C560077:trametinib; D020928:Mitogen-Activated Protein Kinases; C574276:cobimetinib